---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-060286"
form_type: "8-K/A"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2022-05-13T23:59:59+00:00"
generated_at: "2026-06-25T16:24:50.902115+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Collegium files BDSI acquisition pro forma; $669M total consideration, $75M annual synergy target

## Summary
- Total consideration for BDSI acquisition: $669.4M ($606.4M cash to stockholders at $5.60/share + $63.0M to retire BDSI debt).
- Pro forma combined 2021 revenue $443.6M, net income $23.5M after $132.9M in transaction-related adjustments.
- Company expects at least $75M in annual run-rate cost synergies within 12 months of closing (headcount reductions and consolidation).
- Acquisition financed via a new $650.0M term loan (modification of existing Collegium term loan); BDSI term loan paid at close.
- Preliminary purchase price allocation includes $445M in identifiable intangible assets (Belbuca, Symproic, Elyxyb) and $134M in goodwill.

## SEC filing metadata
- accession: 0001104659-22-060286
- form_type: 8-K/A
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2022-05-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465922060286/0001104659-22-060286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465922060286/tm2215301d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-060286
- JSON: https://secwatch.observer/filing/0001104659-22-060286.json
- Plain text: https://secwatch.observer/filing/0001104659-22-060286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.